Skin angiography assisted mastectomy in secondary breast angiosarcoma: Complete clinical response after neoadjuvant immunotherapy

2021 ◽  
Author(s):  
Tammy Ju ◽  
Deshka Foster ◽  
Ashley Titan ◽  
Saleh Najjar ◽  
Gregory R. Bean ◽  
...  
Keyword(s):  
Clinical Response ◽  
Complete Clinical Response ◽  
Neoadjuvant Immunotherapy

scholarly journals Cost Effectiveness of Watch and Wait Versus Resection in Rectal Cancer Patients with Complete Clinical Response to Neoadjuvant Chemoradiation

2021 ◽  
Author(s):  
Christina Liu Cui ◽  
William Yu Luo ◽  
Bard Clifford Cosman ◽  
Samuel Eisenstein ◽  
Daniel Simpson ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Cost Effectiveness ◽  
Clinical Response ◽  
Disease Progression ◽  
Locally Advanced ◽  
Neoadjuvant Chemoradiation ◽  
Complete Clinical Response ◽  
Watch And Wait ◽  
Recurrence Rates ◽  
Life Years

Abstract Background Watch and wait (WW) protocols have gained increasing popularity for patients diagnosed with locally advanced rectal cancer and presumed complete clinical response after neoadjuvant chemoradiation. While studies have demonstrated comparable survival and recurrence rates between WW and radical surgery, the decision to undergo surgery has significant effects on patient quality of life. We sought to conduct a cost-effectiveness analysis comparing WW with abdominoperineal resection (APR) and low anterior resection (LAR) among patients with stage II/III rectal cancer. Methods In this comparative-effectiveness study, we built Markov microsimulation models to simulate disease progression, death, costs, and quality-adjusted life-years (QALYs) for WW or APR/LAR. We assessed cost effectiveness using the incremental cost-effectiveness ratio (ICER), with ICERs under $100,000/QALY considered cost effective. Probabilities of disease progression, death, and health utilities were extracted from published, peer-reviewed literature. We assessed costs from the payer perspective. Results WW dominated both LAR and APR at a willingness to pay (WTP) threshold of $100,000. Our model was most sensitive to rates of distant recurrence and regrowth after WW. Probabilistic sensitivity analysis demonstrated that WW was the dominant strategy over both APR and LAR over 100% of iterations across a range of WTP thresholds from $0–250,000. Conclusions Our study suggests WW could reduce overall costs and increase effectiveness compared with either LAR or APR. Additional clinical research is needed to confirm the clinical efficacy and cost effectiveness of WW compared with surgery in rectal cancer.

Management of Low Rectal Cancer After Complete Clinical Response

2018 ◽  
pp. 289-299
Author(s):  
Angelita Habr-Gama ◽  
Guilherme Pagin São Julião ◽  
Cecilia Beatriz Rossi ◽  
Bruna Borba Vailati ◽  
Rodrigo Oliva Perez
Keyword(s):  
Rectal Cancer ◽  
Clinical Response ◽  
Low Rectal Cancer ◽  
Complete Clinical Response

Ten‐year outcome of curative “exclusive” chemotherapy in N0M0 squamous cell carcinoma of the larynx and pharynx with complete clinical response

Head & Neck ◽  
2019 ◽  
Vol 41 (7) ◽  
pp. 2190-2196 ◽  
Author(s):  
Ollivier Laccourreye ◽  
Grégoire Marret ◽  
François Rubin ◽  
Elizabeth Fabre ◽  
Cécile Badoual ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Response ◽  
Squamous Cell ◽  
Complete Clinical Response ◽  
Carcinoma Of The Larynx

scholarly journals Complete clinical response to intralesional talimogene laherparepvec injection in a patient with recurrent, regionally advanced Merkel cell carcinoma

2019 ◽  
Vol 5 (10) ◽  
pp. 849-851 ◽  
Author(s):  
Michael H.K. Nguyen ◽  
Stanley P. Leong ◽  
Roy Abendroth ◽  
Mohammed Kashani-Sabet ◽  
Kevin B. Kim
Keyword(s):  
Cell Carcinoma ◽  
Clinical Response ◽  
Merkel Cell Carcinoma ◽  
Merkel Cell ◽  
Complete Clinical Response ◽  
Talimogene Laherparepvec
Sign in / Sign up

Export Citation Format

Share Document